Russell H. Tobe

Russell H. Tobe

Auto-generated profile, based on publicly available information

Russell H. Tobe

Nathan S. Kline Institute for Psychiatric Research, Orangeburg, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Biological Psychiatry
Verified
Journal Article
Closed access
AMAntígona Martínez
Antígona Martínez
RTRussell Tobe
Russell Tobe
EDElisa C. Dias
Elisa C. Dias
BABabak A. Ardekani
Babak A. Ardekani
JVJeremy Veenstra-VanderWeele
Jeremy Veenstra-VanderWeele
DJDaniel C. Javitt
Daniel C. Javitt

14 June 2022 in Scientific Data
Verified
Journal Article
Open access
PDF file
RTRussell H. Tobe
Russell H. Tobe
AMAnna MacKay-Brandt
Anna MacKay-Brandt
RLRyan Lim
Ryan Lim
MKMelissa Kramer
Melissa Kramer
MBMelissa M. Breland
Melissa M. Breland
MMMichael Milham
Michael Milham
Most psychiatric disorders are chronic, associated with high levels of disability and distress, and present during pediatric development. Scientific innovation increasingly allows researchers to probe brain-behavior relationships in the developing human. As a result, ambitions to (1) establish normative pediatric brain development trajectories akin to growth curves, (2) characterize reliable metrics for distinguishing illness, and (3) develop clinically useful tools to assist in the diagnosis and management of mental health and learning disorders have gained significant momentum. To this end, the NKI-Rockland Sample initiative was created to probe lifespan development as a large-scale multimodal dataset. The NKI-Rockland Sample Longitudinal Discovery of Brain Development Trajectories substudy (N = 369) is a 24- to 30-month multi-cohort longitudinal pediatric investigation (ages 6.0–17.0 at enrollment) carried out in a community-ascertained sample. Data include psychiatric diagnostic, medical, behavioral, and cognitive phenotyping, as well as multimodal brain imaging (resting fMRI, diffusion MRI, morphometric MRI, arterial spin labeling), genetics, and actigraphy. Herein, we present the rationale, design, and implementation of the Longitudinal Discovery of Brain Development Trajectories protocol.

12 January 2022 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
ESEmily R. Stern
Emily R. Stern
GEGoi Khia Eng
Goi Khia Eng
ANAlessandro S. De Nadai
Alessandro S. De Nadai
DIDan Vlad Iosifescu
Dan Vlad Iosifescu
RTRussell H. Tobe
Russell H. Tobe
KCKatherine Collins
Katherine Collins
Obsessive-compulsive disorder (OCD) is highly heterogeneous. Although perseverative negative thinking (PT) is a feature of OCD, little is known about its neural mechanisms or relationship to clinical heterogeneity in the disorder. In a sample of 85 OCD patients, we investigated the relationships between self-reported PT, clinical symptom subtypes, and resting-state functional connectivity measures of local and global connectivity. Results indicated that PT scores were highly variable within the OCD sample, with greater PT relating to higher severity of the “unacceptable thoughts” symptom dimension. PT was positively related to local connectivity in subgenual anterior cingulate cortex (ACC), pregenual ACC, and the temporal poles—areas that are part of, or closely linked to, the default mode network (DMN)—and negatively related to local connectivity in sensorimotor cortex. While the majority of patients showed higher local connectivity strengths in sensorimotor compared to DMN regions, OCD patients with higher PT scores had less of an imbalance between sensorimotor and DMN connectivity than those with lower PT scores, with healthy controls exhibiting an intermediate pattern. Clinically, this imbalance was related to both the “unacceptable thoughts” and “symmetry/not-just-right-experiences” symptom dimensions, but in opposite directions. These effects remained significant after accounting for variance related to psychiatric comorbidity and medication use in the OCD sample, and no significant relationships were found between PT and global connectivity. These data indicate that PT is related to symptom and neural variability in OCD. Future work may wish to target this circuity when developing personalized interventions for patients with these symptoms.

8 March 2022 in Cerebral Cortex
Verified
Journal Article
Closed access
PDF file
GEGoi Khia Eng
Goi Khia Eng
KCKatherine Collins
Katherine Collins
CBCarina Brown
Carina Brown
MLMolly Ludlow
Molly Ludlow
RTRussell H Tobe
Russell H Tobe
ESEmily R Stern
Emily R Stern
Patients with obsessive–compulsive disorder (OCD) exhibit abnormality in their subjective perception of internal sensation, a process known as interoceptive sensibility (IS), as well as altered functioning of the insula, a key neural structure for interoception. We investigated the multivariate structure of IS in 77 OCD patients and 53 controls and examined associations of IS with resting-state functional connectivity (FC) of the insula within the OCD group. For each group, principal component analysis was performed on 8 subscales of the Multidimensional Assessment of Interoceptive Awareness assessing putatively “adaptive” and “maladaptive” aspects of IS. Associations between IS components and insula FC in the OCD group were evaluated using seed regions placed in each of 3 subdivisions of the insula (posterior, anterior dorsal, and anterior ventral). Behaviorally, controls showed a 2-component solution broadly categorized into “adaptive” and “maladaptive” IS, while OCD patients exhibited a 3-component solution. The general tendency to notice or be aware of sensation loaded onto an “adaptive” IS component in controls but loaded onto both “adaptive” and “maladaptive” IS components in OCD. Within OCD, insula FC was differentially associated with distinct aspects of IS, identifying network connections that could serve as future targets for the modulation of IS in OCD.

11 June 2022 in Molecular Autism
Verified
Journal Article
Open access
PDF file
SJSuma Jacob
Suma Jacob
EAEvdokia Anagnostou
Evdokia Anagnostou
EHEric Hollander
Eric Hollander
RJRoger Jou
Roger Jou
NMNora McNamara
Nora McNamara
JVJeremy Veenstra-VanderWeele
Jeremy Veenstra-VanderWeele
Background: Autism spectrum disorder (ASD) is a common and heterogeneous neurodevelopmental condition that is characterized by the core symptoms of social communication difficulties and restricted and repetitive behaviors. At present, there is an unmet medical need for therapies to ameliorate these core symptoms in order to improve quality of life of autistic individuals. However, several challenges are currently faced by the ASD community relating to the development of pharmacotherapies, namely in the conduct of clinical trials. Balovaptan is a V1a receptor antagonist that has been investigated to improve social communication difficulties in individuals with ASD. In this viewpoint, we draw upon our recent first-hand experiences of the balovaptan clinical development program to describe current challenges of ASD trials. Discussion points: The balovaptan trials were conducted in a wide age range of individuals with ASD with the added complexities associated with international trials. When summarizing all three randomized trials of balovaptan, a placebo response was observed across several outcome measures. Placebo response was predicted by greater baseline symptom severity, online recruitment of participants, and less experienced or non-academic trial sites. We also highlight challenges relating to selection of outcome measures in ASD, the impact of baseline characteristics, and the role of expectation bias in influencing trial results. Conclusion: Taken together, the balovaptan clinical development program has advanced our understanding of the key challenges facing ASD treatment research. The insights gained can be used to inform and improve the design of future clinical trials with the collective aim of developing efficacious therapies to support individuals with ASD.

12 April 2023 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
RTRussell Tobe
Russell Tobe
YZYajing Zhu
Yajing Zhu
TGTeresa Gleissl
Teresa Gleissl
SRSimona Rossomanno
Simona Rossomanno
JVJeremy Veenstra-VanderWeele
Jeremy Veenstra-VanderWeele
EHEric Hollander
Eric Hollander
High rates of placebo response are increasingly implicated in failed autism spectrum disorder (ASD) clinical trials. Despite this, there are limited investigations of placebo response in ASD. We sought to identify baseline predictors of placebo response and quantify their influence on clinical scales of interest for three harmonized randomized clinical trials of balovaptan, a V1a receptor antagonist. We employed a two-step approach to identify predictors of placebo response on the Vineland-II two-domain composite (2DC) (primary outcome and a caregiver measure) and Clinical Global Impression (CGI) scale (secondary outcome and a clinician measure). The initial candidate predictor set of variables pertained to participant-level, site-specific, and protocol-related factors. Step 1 aimed to identify influential predictors of placebo response using Least Absolute Shrinkage and Selection Operator (LASSO) regression, while Step 2 quantified the influence of predictors via linear regression. Results were validated through statistical bootstrapping approaches with 500 replications of the analysis dataset. The pooled participant-level dataset included individuals with ASD aged 5 to 62 years (mean age 21 [SD 10]), among which 263 and 172 participants received placebo at Weeks 12 and 24, respectively. Although no influential predictors were identified for CGI, findings for Vineland-II 2DC are robust and informative. Decreased placebo response was predicted by higher baseline Vineland-II 2DC (i.e., more advanced adaptive function), longer trial duration, and European (vs United States) sites, while increased placebo response was predicted by commercial (vs academic) sites, attention deficit hyperactivity disorder and depression. Identification of these factors may be useful in anticipating and mitigating placebo response in drug development efforts in ASD and across developmental and psychiatric conditions.